Introduction
Gonococcal infection, caused by Neisseria gonorrhea, is a growing clinical and public health issue due to increasing rates, patterns of antimicrobial resistance and its association with long term health sequelae when left untreated or treated ineffectively. Among women, untreated gonorrhea is associated with pelvic inflammatory disease, ectopic pregnancy, or infertility; among men, it is associated with epididymitis or infertility (1, 2) . In Canada, reported cases of gonorrhea have increased by 38.9% between 2003 and 2012, with rates highest among 20-24-year-old men (148.5 per 100,000) and women (153.0 per 100,000) (3).
In addition to rising rates of gonorrhea, antimicrobial resistant N. gonorrhea has been increasing (4) including strains resistant to ceftriaxone (5) . The Government of Canada has identified antimicrobial resistance as a priority area for action, and in 2013, the Public Health Agency of Canada (PHAC) released updated recommendations for the treatment of gonorrhea in their Canadian Guidelines on Sexually Transmitted Infections. These guidelines recommend combination antibiotic therapy, with the choice of medications varying by population and site of infection (6,7) ( Table 1) . Combination antibiotic therapy is recommended as the preferred therapy. It provides treatment with antibiotics acting through two different mechanisms which reduces the likelihood of treatment failure, addresses the emergence of RESEARCH multi-drug resistant gonorrhea, and provides effective treatment for chlamydia (8) (9) (10) (11) (12) . However, other guidelines are available and may inform the practice of primary care physicians.
Findings from Canadian sexual health clinics suggest that combination therapy is prescribed at least 76% of the time (13) , however, there is a paucity of evidence documenting primary care physicians' prescribing practices. Primary care health professionals have an important role in the prevention and management of antimicrobial resistant gonorrhea.
The objectives of the study were to describe primary care physicians' knowledge related to the management of antimicrobial resistant (AMR) gonorrhea and to identify their prescribing preference for three clinical scenarios.
Methods

Survey
PHAC commissioned two online cross-sectional surveys from an online survey company who recruits physicians across Canada who agree to be contacted for surveys. In April 2014 and March 2015, participating physicians were invited to take a 20-minute online survey with both open-and closed-ended questions. Survey questions were derived from previously developed questionnaires and were tested for face validity with PHAC nurses, physicians and epidemiologists. Physicians were asked to answer 14 true/false statements regarding the epidemiology, diagnosis, management and public health reporting of AMR gonorrhea. Open-ended responses for three clinical scenarios were solicited: 1) Suspected anogenital infection drawing from a population of MSM; 2) suspected anogenital infection drawing from a non-MSM population; and 3) suspected pharyngeal infection drawing from any population. Physicians received a financial incentive for completing the survey.
In 2015, a question was added to clarify physicians' reasons for prescribing the second antibiotic, azithromycin, for the treatment of gonorrhea.
Data analysis
Data were analyzed using SAS EG (v5.1). Pearson's chi-square test was used to compare the two samples. The datasets from both survey cycles were combined for analysis because no differences were found between the sample populations. The frequency of correct responses was calculated for each of the true/false statements on the diagnosis, treatment, follow-up and public health reporting of gonorrhea. The open-ended responses for the three clinical scenarios were recoded into the following treatment options: ceftriaxone and azithromycin; cefixime and azithromycin; cephalosporin alone; azithromycin alone; spectinomycin with azithromycin and other pharmaceutical regimens. Dosing information and route of administration were not considered due to large amounts of missing data. Physicians who indicated "not applicable", "do not treat men", "not sure", or "don't know" were grouped under "no treatment information".
Results
A total of 2500 physicians were contacted for the first survey and 321 completed the survey for a response rate of 13%. A total of 3600 physicians were contacted for the second survey and 304 completed the survey for a response rate of eight percent. A total of 625 physicians completed the two surveys.
Physicians' demographics and characteristics
Two thirds of respondents were male (66%), 83% of physicians had 10 or more years of practice and 85% worked in family medicine. Almost 75% of respondents encountered at least one case of gonorrhea in the previous year ( Table 2) . Knowledge related to the management of antimicrobial resistant gonorrhea
Overall, 60% to 95% of physicians accurately identified knowledge statements regarding pharmaceutical management, partner notification and public health reporting. Approximately two thirds of the respondents accurately identified statements related to current trends in rising incidence, the most common age groups affected and the presence of antimicrobial resistant gonorrhea in Canada (Table 3) . Most respondents (87%) identified the importance of co-treatment for chlamydia.
An additional question on the reason for prescribing a second antibiotic was added in the 2015 survey, and 49% identified it was for presumptive treatment for both gonorrhea and chlamydia and 41% identified it was for presumptive treatment for chlamydia ( Figure 1 ).
Physicians' prescribing practices Table 4 summarizes the data for prescribing practices. For all clinical scenarios, 30%-35% of physicians did not provide any treatment information, approximately 30% of physicians indicated treating with cephalosporin monotherapy, 20%-25% indicated they would prescribe a cephalosporin and azithromycin; and a minority of physicians identified other treatment options.
As regards to MSM patients presenting with suspected anogenital infection, almost 30% of physicians did not identify any treatment options, almost 30% indicated they would prescribe cephalosporin alone, 25% indicated they would prescribe a cephalosporin and azithromycin, five percent identified azithromycin alone and the rest identified other treatment options. With respect to non-MSM patients presenting with uncomplicated gonorrhea anogenital infection, 30% of physicians reported using cephalosporin monotherapy, 25% reported combination therapy with a cephalosporin and azithromycin; eight percent indicated treating with azithromycin alone and 13% reported using other antibiotic regimens. For the treatment of patients with pharyngeal infection, slightly over 
Discussion
These online surveys found that participating physicians were knowledgeable about the pharmaceutical management, partner notification, and public health reporting of N. gonorrhea, but appeared to be less knowledgeable about the use of combination therapy to deter the development of antimicrobial resistant gonorrhea. Approximately 25% reported their intent to prescribe the specific combination therapy for anogenital infection identified by the Canadian Guidelines on Sexually Transmitted Infections as the preferred therapy to prevent treatment failure and to mitigate the development of antimicrobial resistance. Responding physicians appeared to be less confident in prescribing for pharyngeal gonorrhea. These findings are in contrast to studies of sexual health clinics, where prescribing combination therapy is routine (14) (15) (16) (17) .
Monotherapy for the treatment of gonorrhea is not recommended as treatment failures with oral cefixime monotherapy have been documented in Canada (12, 18, 19) . In our sample, approximately 30% of physicians indicated they would treat gonorrhea with a cephalosporin monotherapy; however, close to half of physicians reported the purpose of the second antibiotic (often azithromycin) was for chlamydia only (and not gonorrhea) and 87% believed that co-treatment for chlamydia is advisable when treating for gonorrhea. As such, it is hypothesized that primary care physicians may be prescribing combination therapy, but largely to cover possible co-infection.
There are some limitations to consider. 
Conclusion
In light of the rising incidence of gonorrhea and AMR gonorrhea, increasing awareness and uptake by primary care physicians of the routine use of combination therapy may help minimize treatment failure and deter the development of AMR gonorrhea. Objective: The aim of this document is to outline the methodological protocol of a systematic review that would gather evidence for the optimal frequency of HIV testing among individuals in various HIV risk groups with respect to personal and public health outcomes and cost-effectiveness.
Methods: This protocol adheres to the PRISMA-P reporting items, and the review is registered with PROSPERO. The target population includes individuals who may have undiagnosed HIV infection. Different frequencies of HIV testing will be compared and outcomes to do with personal and public health, patient values/preferences and costs will be examined. The search strategy will encompass searches in MEDLINE/Pubmed, Scopus, Embase, Cochrane, PsychINFO, and EconLit, as well as grey literature sources. Articles will be screened by title/ abstract, and subsequently by full-text, in duplicate. Extraction of pertinent data from the screened references will be carried out by one reviewer and verified by a second. Multiple critical appraisal tools will be used to assess individual study quality, and the GRADE approach will be used to appraise the overall quality of the evidence. Data will be synthesized narratively, and the results will be published in a peer-reviewed journal.
Discussion: This systematic review, designed with extensive input from content experts, will help to identify key evidence to inform recommendations for HIV testing frequency. Many of the guidelines reviewed in the systematic review of guidelines mentioned above are several years old. In addition, guideline developers do not always describe the basis for their recommendations (e.g. systematic review versus expert opinion). A thorough, up-to-date review of scientific evidence related to HIV testing frequency is warranted and will be useful for developing timely quality guidance in Canada and abroad. The purpose of this article is to describe the protocol for a systematic review aimed at answering a number of questions related to how often to test for HIV.
Objective
The objective of the systematic review is to examine the scientific evidence that supports different frequencies of HIV testing for individuals in various risk groups who may have undiagnosed HIV.
The over-arching research question is: What is the optimal frequency of testing for HIV in individuals from various HIV risk groups with respect to personal and public health outcomes and cost-effectiveness? The sub-questions relevant to this include:
• 
Methods
Prior to the development of this protocol, a scoping search was completed to help guide protocol development and identify any similar works. This scoping search included a review of the reference lists from key guidelines identified in a systematic review of HIV testing guidelines (9) as well as searches for the term "HIV testing" on the websites of the following organizations/registries: Cochrane, the National Institute for Health and Care Excellence (NICE), the Canadian Agency for Drugs and Technologies in Health (CADTH), the UK Department of Health (NHS), the International Resource for Infection Control (iNRIC) and the PROSPERO International Prospective Register of systematic reviews.
This systematic review protocol has been designed in alignment with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) (11) . See Appendix 1 for a list of the PRISMA-P reporting items.
Drafts of the protocol were peer-reviewed by several experts in infectious disease guideline development from the Public Health Agency of Canada prior to registration of the review with the PROSPERO International Prospective Register of systematic reviews (http://www.crd.york.ac.uk/PROSPERO; registration number CRD42016046575) (12) . In addition, a health economist was consulted.
Search strategy
A comprehensive search strategy was designed in consultation with a research librarian. The search strategy was also peer-reviewed by an external research librarian prior to execution of the search. The full search strategy can be found in Appendix 2.
The following databases will be searched:
The following sources of grey literature will be searched:
• Open Grey • ClinicalTrials.gov • All relevant sources from the CADTH Grey Matters checklist (13) The search strategies that will be used for Open Grey and ClinicalTrials.gov can be found in Appendix 3.
The CADTH Grey Matters tool is a checklist used to guide online searches for grey literature. It includes national and international health technology assessment websites, drug and device regulatory agencies, clinical trial registries, health economics resources, Canadian health prevalence or incidence databases and drug formulary web sites (13) . A total of 40 relevant websites from the checklist were identified by the research team (drug formulary, drug advisory and warning, and surveillance databases were not considered relevant to the research question, for example). Many of the websites in the checklist do not include an advanced search option, so the large majority will be searched using the term "HIV" to provide the widest range of potentially relevant results. Websites with advanced search functions will be searched with combinations of "HIV" and "testing" or "screening" or "test" or "screen."
Grey literature searches will be carried out by two members of the research team independently, and all articles deemed potentially relevant will be added to the results of the database searches for further screening.
Data management
All references will be uploaded into the DistillerSR, a secure, internet-based systematic review management software (Evidence Partners). This software platform will be used for screening eligible articles, data extraction and quality assessment.
Eligibility criteria Language
Articles published in English or French will be considered for the review.
SYSTEMATIC REVIEW
Study design
Eligible study designs will vary depending on the specific research sub-question. For all search questions, other systematic reviews will not be explicitly excluded. Rather, the reference lists will be scanned for relevant articles that may have otherwise been missed. Table 1 outlines the study designs that will be considered for each of the research sub-questions.
Population
The target population includes individuals who may have undiagnosed HIV infection.
Intervention
The intervention of interest is HIV screening/testing at varying intervals.
Comparison
The effects of the intervention will be compared to any the following:
• Other interventions • "Normal" or "standard" state of care (as defined in a given study) • Before/after comparisons Setting Studies will be considered if they are held in any setting where HIV testing could be conducted.
Exclusion criteria
Articles will also be excluded if they are:
• Published prior to 2000 • Commentaries, editorials, letters to the editor, conference abstracts, poster presentations • Guidelines/ policy papers/ policy documents
Outcomes
Several potential outcomes that could be relevant for each of the research sub-questions have been identified. However, the possibility exists that not all of the outcomes will be represented in the literature, as some may not have been examined. The primary and secondary outcomes of interest for each research question are outlined in Table 2 .
Screening/selection of articles
All references identified in the search will be screened based on title and abstract following removal of duplicates. The eligibility criteria above will be used to determine inclusion and exclusion Primary outcomes:
• Time between HIV exposure/infection and diagnosis What is the most cost-effective frequency or interval of re-testing for HIV in people who have an unknown or a previously confirmed negative serostatus?
• All outcomes from the pertinent study types will be considered Abbreviations: CD4, cluster of differentiation 4; HIV, human immunodeficiency virus; ART, antiretroviral therapy of articles at the title/abstract-screening stage. Screening of titles and abstracts will be performed in duplicate by two reviewers. Disagreements will be reconciled through discussion with a third reviewer.
Full-text screening will be performed on titles with abstracts that meet the above criteria or for cases in which it is unclear whether this is the case. At the full-text screening stage, the eligibility criteria, as well as the outcomes listed above, will guide exclusion of irrelevant articles. Full-text screening will be performed in duplicate by two reviewers. Disagreements will be reconciled through discussion with a third reviewer.
Reasons for exclusion will be recorded at each step of the screening process. The results of the screening will be presented in a flowchart consistent with PRISMA recommendations (14) .
Data extraction
Extraction of pertinent data from the screened references will be carried out by one reviewer and verified by another in order to reduce bias or errors in extraction. Any disagreements will be resolved through discussion with one or two other reviewers. Study authors may be contacted if there are any major uncertainties. All pertinent data (i.e. year of publication, period of data collection, study population, sample size, location, study setting, study design, intervention, comparison, results/ outcomes, quality assessment score, etc.) will be extracted into evidence tables. Duplicate, overlapping or companion studies, if identified during the screening process, will be dealt with by extracting the data into a single collection form or by extracting the data separately and combining these into a single input afterwards, as per the Cochrane Handbook for Systematic Reviews of Interventions (15) .
Quality assessment
Quality assessment will be carried out for individual studies included in the review, as well as for the overall body of evidence. Different methods of assessment will be used as appropriate for the study type.
The following assessment tools will be used for individual studies:
• Cochrane risk of bias for RCTs (15) • Effective Public Health Practice Project (EPHPP) Quality Assessment Tool for other quantitative studies (16-18) • Critical Appraisal Skills Programme (CASP) Qualitative
Checklist for qualitative studies (19) For the overall body of evidence, the quality of evidence will be assessed using the GRADE approach (15).
Data synthesis
Data will be synthesized narratively. If there is sufficient homogeneity among the evidence, a meta-analysis may be considered, although this is unlikely due to the variety of evidence sources being sought.
Subgroup analysis
The initial search will not target any specific subgroups. If evidence emerges for specific subgroups (e.g. MSM, IDU, Indigenous peoples, etc.) then the results will be disaggregated and reported narratively in separate sections for each subgroup.
Assessment of meta-biases
Statistical assessment of meta-biases such as publication bias across studies (e.g. Egger's test) will likely not be possible given the wide variety of evidence being sought and the likelihood of inclusion of a large proportion of studies with observational designs (20) . The potential for publication bias will however be reduced by employing a rigorous search of grey literature, and the potential for substantial publication bias in observational studies will be taken into account when assessing the overall body of evidence using the GRADE approach (20) . Selective outcome reporting will be assessed in RCTs by comparing the reported results of studies with the outcomes reported in the methods section of the protocol of the study. This will factor into quality assessment with the Cochrane risk of bias tool (15) .
Amendments
The research team does not foresee any amendments to the protocol prior to carrying out the systematic review. However, if this is necessary, all amendments will be recorded as they occur and reflected in the PROSPERO record for this review. Amendments will also be documented in the final publication.
Dissemination
A manuscript of the results of the systematic review will be prepared and submitted for publication in a peer-reviewed journal. The results will be presented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (14) .
Discussion
To the best of our knowledge, this will be the first published systematic review examining evidence supporting recommendations for HIV testing frequency. The evidence identified in this review may be useful to update or create new guidance around HIV testing in Canada; groups outside Canada may also find it useful. The development of specific, evidence-based recommendations will help health care providers streamline and improve their HIV testing practices. Such recommendations can also be used by the public to manage their own sexual health.
Enhanced HIV screening and testing will help decrease the substantial portion of individuals with HIV who are unaware of their infection. This group contributes to a substantial proportion of new HIV infections, and evidence suggests that once these individuals are aware of their infection, they will be more likely to take steps to minimize the likelihood of transmission (4, 21) . HIV diagnosis is also the first step toward obtaining treatment, and thus, enhanced screening and testing yields benefits for personal and public health.
SYSTEMATIC REVIEW
The strengths of this systematic review protocol include extensive input from content experts in the development of HIV and sexually transmitted infection guidelines and health economics. Another strength is the external peer review of the research librarian-designed search strategy.
One limitation of the review could be the potential inclusion of predominantly observational studies, given the difficulty of carrying out experimental studies on the topic. This may raise concerns regarding the quality of evidence; however, the results of the quality assessments will be published, and thus assessment of bias in the evidence will be transparent.
If this systematic review fails to find evidence to answer one or more of the research questions, this will be documented in the results. A "negative" finding will still be of use to guideline developers as it provides validity to those guidelines that cite a lack of evidence for HIV-testing interval recommendations (9) and suggests that such recommendations may need to be made on a jurisdiction-by-jurisdiction basis, based on expert opinion. It would also help highlight gaps in evidence, which could be useful for guiding future research. Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 137 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
175-187
Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators
188-199
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
192-194
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale Open Grey ("HIV" OR "HIV+" or "HIV-1" OR "HIV-2" OR "HIV1" OR "HIV2" OR "HIVAIDS" OR ("human immun*" NEAR/2 "virus") OR "human immunodeficiency virus" OR "human immunodeficiency virus infection") AND ("screening" OR "test*" OR "retest*" OR "rescreen*" OR "re-test*" OR "re-screen*")
Results: 163 items returned Link to results: http://www.opengrey.eu/search/request?q=%28%22HIV%22+O R+%22HIV%2B%22+or+%22HIV-1%22+OR+%22HIV-2%22+OR+ %22HIV1%22+OR+%22HIV2%22+OR+%22HIVAIDS%22+OR+% 28%22human+immun*%22+NEAR%2F2+%22virus%22%29+OR +%22human+immunodeficiency+virus%22+OR+%22human+im munodeficiency+virus+infection%22%29+AND+%28%22screeni ng%22+OR+%22test*%22+OR+%22retest*%22+OR+%22rescre en*%22+OR+%22re-test*%22+OR+%22re-screen*%22%29+
ClinicalTrials.gov Advanced search:
Conditions: "HIV" OR "HIV+" or "HIV-1" OR "HIV-2" OR "HIV1" OR "HIV2" OR "HIVAIDS" OR "human immununodeficiency virus"
Interventions: "screening" OR "testing" OR "retesting" OR "rescreening" OR "re-testing" OR "re-screening" Objective: To assess the use of a 40-day rolling incidence rate to monitor pertussis activity in Nova Scotia.
Intervention: A 40-day rolling incidence rate was calculated for pertussis by age groups and various levels of geography. Public health authorities continued to anticipate new cases of pertussis if the contacts of known cases were still within the incubation period (range between six and 20 days). The 40-day incubation period was chosen to reflect twice the incubation period's upper range. Rates were calculated using Statistics Canada population projections for 2014 and then compared with traditional case counts and cumulative incidences. The usefulness of the statistics was assessed by public health decision makers.
Outcomes: Increased pertussis activity was noted across NS, most notably in the South West region. The use of a 40-day rolling incidence rate as a surveillance tool provided more timely and geographically precise descriptions of ongoing trends in pertussis activity and helped to inform appropriate public health action. Health officials valued the information provided from the rolling incidence because it allowed them to manage activities based on weekly estimates at various levels of geography.
Conclusion:
Rolling incidence proved to be a useful tool to monitor a cyclical increase in pertussis cases in Nova Scotia and to inform related public health actions. The rolling incidence provided geographically precise and timely information that was useful to estimate new cases in the absence of reliable immunization coverage information. This method could supplement traditional epidemiological surveillance of future communicable disease events, especially those characterized by long incubation periods and low case counts. 
Introduction
Pertussis (whooping cough) is a highly contagious respiratory infection caused by Bordetella pertussis bacteria. It is endemic in the human population and challenging to control in part due to a long communicable period (six to 20 days) (1-3), under-immunization of the population and evidence of waning vaccine immunity. Illness may be particularly severe in children under 12 months (1) with complications including pneumonia, seizures, encephalopathy, hernias and death (4) . Milder forms of the disease may manifest in adults and adolescents who are less likely to be diagnosed and treated (5, 6) . Evidence suggests that children are falling behind in immunizations (7, 8) and immunity post vaccination may wane over time (9, 10) creating a vulnerable population that contributes to an ongoing reservoir of pertussis in humans (11, 12) .
Pertussis activity can be cyclical in nature (13) (14) (15) . Between January 1 and December 31, 2015, Nova Scotia (NS) experienced an increase in the number of pertussis cases. This triggered a need to more closely monitor and analyze pertussis activity within the Province. The structure of the health system in NS comprises two health authorities, the Nova Scotia Health Authority (NSHA) (subdivided into four local management zones) and the Izaak Walton Killam (IWK) Health Authority. In line with recommendations from Canada and the World Health Organization for pertussis surveillance (16, 17) , notifiable disease data is reported monthly at the zone and provincial levels and on an annual basis at the provincial level.
IMPLEMENTATION SCIENCE
During the 2015 pertussis outbreak, monthly and annual surveillance reports did not fully meet the information needs of local public health authorities to respond to the increase in the number of pertussis cases. Given that NS is a small province (total population less than one million), frequently reporting on pertussis activity (e.g. weekly) and by health zone (or lower level geographies) presents challenges due to small case counts. Findings are statistically less reliable when disease events are rare (18) and reporting low counts may threaten confidentiality, especially in smaller populations (19, 20) .
To mitigate the challenges presented by small numbers, other options were considered. The year-to-date cumulative incidence was considered problematic as it did not accurately reflect current disease activity. Because cumulative incidence was calculated with a static denominator, the trend line simply increased weekly so it did not reveal increases or decreases from week to week. The attack rate was also considered, but poor immunization coverage data made it difficult to quantify the susceptible populations.
Public health authorities decided to try a 40-day rolling incidence rate. The 40-day interval was chosen to conservatively reflect twice the upper range of the six to 20-day incubation period. Rolling estimates have been used in outbreak situations (21), often in the form of an arbitrary five year rolling average to define normal activity or establish baselines for comparisons. To the best of the authors' knowledge, this is the first documented use of a rolling incidence rate developed to reflect disease specific qualities (i.e. incubation period) and to anticipate disease activity.
The objective of this article is to describe the first use of a 40-day rolling incidence rate to monitor pertussis activity and to assess whether this method assisted in guiding public health action. This method supplemented routine surveillance during an increase in pertussis activity in NS between January 1 and December 31, 2015.
Intervention Data sources
Confirmed pertussis cases reported based on episode date
The Application for Notifiable Disease Surveillance (ANDS) was used for ongoing surveillance of NS pertussis cases that met the provincial case definitions (confirmed, probable and suspect) (22) . Demographic information (including age and geographical area of residence) were also extracted from ANDS using COGNOS, a commercial software extraction, analysis and reporting package. This information was used to calculate the number of confirmed pertussis cases based on reported episode date by month and geographical area. Episode date most often referred to the onset date of symptoms. Clinical diagnosis date was used if onset date was unavailable and specimen collection date was used if neither onset date nor clinical diagnosis date were available. Lab test result date was used only when no other dates were available (23) .
Data analysis Traditional statistics
Cases reported between January 1, 2015 and December 31, 2015, were extracted monthly from ANDS using COGNOS. Traditional statistics including monthly counts and rate per 100,000 were calculated monthly for the Province overall and by zones.
Rolling incidence
Retrospective cases from 2015 and the last 40 days of 2014 were used to calculate the rolling incidence rates for all of 2015 (based on episode date). Confirmed cases reported between November 21, 2014 and December 31, 2015 were extracted from ANDS using COGNOS and used to calculate the 40-day rolling incidence rates for 2015.
For each calendar day in 2015, the incidence of pertussis was calculated for the previous 40-days using the reported episode date. The 40-day incidence rate was chosen because it represented twice the outer range of days for the typical incubation for pertussis (range 6-20 days) (1, 3) . Based on an average maximum incubation period of 20 days, a case and any relevant contacts were considered non-infectious 40 days the from the episode date of the case.
Rolling incidence (MI) was defined as the sum of cases (A) over the previous n days divided by the person-time (PT) (mathematical equation available upon request).
Populations were assumed to be static and all at risk, thus each person in the respective populations contributed one unit of time to the denominator. The rolling incidence was calculated for each calendar day (t) by summing the number of pertussis cases (A) within the previous 40-days over the person-time.
Rates were calculated in Stata (24) using 2014 demographic data from Statistics Canada (25) . Rates per 100,000 population were calculated at different geographies, including four provincial health management zones and the South West geographic area -a sub-section of the Western Zone that concerned local health officials.
Assessing the usefulness of traditional methods and the 40-day rolling incidence rate
The rolling incidence methods were developed through an iterative process. To supplement monthly and annual reporting, the Population Health Assessment and Surveillance team (PHAS) first created a weekly report that included pertussis case counts by zone and age groups. This data was disseminated to public health staff, Medical Officers of Health (MOHs), epidemiologists and communicable disease managers at the provincial Department of Health and Wellness (DHW) and local (NSHA) levels of the public health system. The rolling incidence rate was developed as an additional statistic based on the feedback received from public health stakeholders. Throughout 2015, the PHAS team not only collected stakeholder feedback with respect to the usefulness of the weekly information but also summarized the usefulness of the rolling incidence rate to inform public health action.
Outcomes Pertussis activity
One hundred thirty-six (136) cases of pertussis were reported in NS between January 1 and December 31, 2015. Of those, 105 (76.5%) met the case definition for a confirmed case based on laboratory confirmation or an epidemiological link to a laboratory confirmed case, 10 (7.4%) were probable cases and 21 (15.4%) were suspect cases. The cases ranged in age from 0 to 62 years, with a mean age of 15.6 years. The highest proportion of cases was reported in individuals 20 years and older, while the highest cumulative incidence rate occurred in those under five years ( Table 1) . By December 31, 2015, the provincial cumulative incidence rate was 11.2 per 100,000 population (Table 1) .
Cases were reported from all four provincial health management zones: 9.5% (Northern), 10.5% (Eastern), 30.5% (Central) and 49.5% (Western). The highest cumulative incidence (26.4 per 100,000) in the Province was reported in the Western Zone with 43.8% of the provincial cases in South West. By the end of 2015, the annual incidence rate of pertussis in the South West was 81.6 per 100,000.
Comparing the different surveillance tools
Traditional methods were reported monthly. They showed that the number of cases first peaked in May, 2015 and began to drop after September, 2015. A maximum of 20 confirmed cases were reported monthly ( Figure 1 ) with an average of 2.0 cases per week during 2015 (range of 0 to 7 cases). At the zone level, there was an average of 0.2, 1.0, 0.2 and 0.6 cases per week for the Eastern, Western, Northern and Central Zones, respectively. Feedback from public health stakeholders highlighted difficulties in stratifying and contextualizing these low case counts. Additionally, they reported difficulty identifying temporal trends by zones or smaller geographic areas using only counts. Based on feedback, weekly 40-day rolling incidence rate graphics were created for various levels of geography (province, zones, area) and age groups.
Following the implementation of the 40-day rolling incidence rate into weekly reporting, stakeholders reported that the new format was useful because it was much more timely than monthly reporting. The 40-day rolling incidence statistic provided clear and contextual representation of disease activity within each zone, when compared to weekly case counts. This statistic was useful to explore temporal trends in zonal and sub-zonal areas within NS not possible with count data. For example, over time, cases from the Western Zone ( Figure 2 ) produced a bimodal pattern with rolling incidence peaks in July and again in October 2015. Cases in the Eastern Zone followed a single wave, which peaked in October, while cases in the Northern Zone, increased earlier and peaked in August. Weekly counts were also limited in their usefulness because they could not account for the variation in population sizes across zones or age groups. Weekly case counts of pertussis in the Central Zone were relatively high compared to other zones, likely because of the large population. However, the rolling incidence statistic could contextualize IMPLEMENTATION SCIENCE pertussis activity and the resulting analysis demonstrated that activity in the Central Zone was generally lower and more sporadic, without the clear large peaks observed in other zones.
By July 1, 2015, the provincial year-to-date cumulative incidence rate for pertussis was 4.2 per 100,000 population; 10.2 per 100,000 in the Western Zone and 31.9 per 100,000 in the South West area. Stakeholders requested a statistic that was more reflective of the current activity level, as weekly case counts or annual cumulative incidence rates were not useful to inform the implementation of interventions across various geographic levels. Case counts were too small to provide meaningful comparisons as they were not adjusted for population size, while annual cumulative incidence exaggerated the current disease activity as the non-contagious cases were not removed from the estimates. In comparison, on July 1 the 40-day rolling incidence was 0.5 per 100,000 population in NS, 8.1 per 100,000 in the Western Zone and 24.8 per 100,000 in the South West area (Figure 3) . The 40-day rolling incidence highlighted the need for interventions within the South West area as recommended by the local MOH. Similarly, the rolling incidence estimates did not support the implementation of zone-or province-wide public health actions.
The analysis was important in informing appropriate public health action at different geographic levels. Figure 3 provides a comparison of rolling incidence rates across three levels of geography. Activity was slightly elevated across the Province, with the highest rates observed in the South West area of the Western Zone. Local providers in the South West area were requested to focus on the immunization of children to bring them up-to-date with provincial guidelines, particularly for those 0-4 years of age and to offer immunizations to all pregnant women over 26 weeks gestation, regardless of their immunization status. The latter recommendation differed from the provincial recommendation that only pregnant women 26 weeks gestation or greater who had not received a dose of pertussis vaccine in adulthood be vaccinated, yet was in keeping with the National Advisory Committee on Immunization (NACI) recommendations for pertussis based on local epidemiology that demonstrated increased activity (26) .
Intervention experience
During the period of increased pertussis incidence in NS, there was considerable debate about whether there was a need to intensify control interventions in either the whole or parts of the Province. The 40-day rolling incidence provided greater insight into the timing of peak pertussis incidence and thereby informed a decision by provincial public health authorities that additional control measures instituted in the geographical area of highest activity were not required at a provincial level. Stakeholders reported that they valued the additional information provided by the 40-day rolling incidence rate.
Discussion
During the increase in the reported number of pertussis cases in 2015, the use of the 40-day rolling incidence was found to be a useful way to visualize surveillance data to illustrate regional and temporal trends in NS. This led to the initiation of an urgent vaccination program in part of a health management zone in response to disease activity.
The increased number of pertussis cases in NS throughout 2015 was concerning as it far exceeded the counts and rates observed on average and in the previous cyclical peak of 2012 (27) . This increased activity was successfully described using a 40-day rolling incidence rate.
The use of rolling estimates is not a new technique; rolling averages have been used in other forms of surveillance, such as the development of alert thresholds in syndromic surveillance (28) (29) (30) . Although rolling averages have been used to set thresholds in other research, this use was not the purpose of the study. An additional benefit of the rolling incidence approach is its potential to define and monitor thresholds of disease occurrence.
There were two main strengths associated with use of the 40-day rolling incidence during this public health event. First, the 40-day rolling average provided a timely visual tool to compare statistics across different subpopulations, using information that was more timely than that provided in monthly notifiable disease reports. These comparisons could not be made using a standard epidemiological curve of case counts. For example, in this event, the increasing trend in the Western Zone was not as obvious from the traditional monthly count, but more evident in the plot of the 40-day rolling average.
Second, use of a 40-day rolling average helped avoid some of the complications associated with reporting small numbers of cases and helped to disentangle the issues behind the steadily rising cumulative rate. Reporting low numbers can also threaten the confidentiality of individuals (19, 20) and small numbers are also more affected by chance. This instability can be addressed by either collapsing categories to increase the count (31) or, as in this article, expanding the time interval. NS is a small province with a population of less than one million residents. When pertussis rates are elevated, the actual count of cases remains a small number, especially when stratified by zone. 
Limitations
There are several limitations to the 40-day rolling incidence rate. Although this analysis provided disease specific incidence information to public health decision makers, it is a method not traditionally used and thus its results are not comparable to pertussis rates in other jurisdictions. There are few published discussions of incidents where public health interventions for pertussis have been initiated or discontinued using this type of analysis. In New Brunswick, a pertussis outbreak was declared over when activity returned to within two standard deviations of a five year smoothed rolling average for at least two weeks (28) however this is a much larger timeframe than that used in the analysis. The use of communicable periods to define time intervals might provide an indication of current community transmission but does not consider the additional factor of the known cyclical nature of the disease, where peaks can last for several months and recur over a three to five year time span. A longer timeframe may be required to define optimal thresholds for initiating or discontinuing community control interventions. Additionally, since the number of cases is very small, visualization of the data may be distorted. For example, the bimodal characteristic observed in this analysis could be random noise, an artefact of the rolling average process. Therefore, graphics should be interpreted caution when they reflect low counts.
Using episode date is another weakness of this analysis. In NS, the episode date is the date of symptom onset. The definition of episode date may vary across jurisdictions and may reflect date of report, date of lab confirmation or date of symptom onset. As such, the usefulness of comparing rolling incidence across jurisdictions may be limited.
The 40-day time interval might not be the best or most accurate interval to represent the infectious potential of pertussis within NS. The evidence suggests that the longest incubation period could be 42 days (2), thus a 42 day time frame might be a more complete representation of potential communicability. Alternatively, using the average incubation period of 10 days, might also be insightful as to the probable propagation of disease. Additional research and analysis is needed to validate the optimal time interval for reporting moving incidence. Communicability of pertussis depends on the disease stage and whether a patient receives treatment. Cases are most contagious in the catarrhal and early paroxysmal stages (first two weeks), after which communicability gradually decreases over the next three weeks (1,2). Furthermore, cases are no longer contagious after five days of treatment with antibiotics. During this public health event, several cases in families were diagnosed retrospectively. These retrospective cases likely did not benefit from treatment and were therefore probably communicable for longer time intervals. The communicability period was assumed to be the same for all cases included in the 40-day rolling incidence calculations. Cases that received treatment and those that continued to spread the disease were both included. Moreover, delayed reporting of cases limits the real-time effectiveness of this method.
Despite the limitations of the methodology, rolling incidence can be used in conjunction with traditional communicable disease surveillance methods, especially in instances that involve rare public health events, with long incubation periods. There is potential for these methods to be employed in similar situations as they complement traditional epidemiological methods for surveillance of notifiable diseases. Going forward, rolling incidence could be used to define and monitor thresholds of disease occurrence. This will be an area for public health authorities to consider as they continue efforts to improve surveillance for communicable disease. Therefore, graphics should be interpreted with caution when they reflect low counts.
Conclusion
Forty day rolling incidence rates provided a useful way to describe and compare pertussis trends within NS for various geographic levels and age groups. The 40-day rolling incidence rate proved to be a useful supplementary tool to investigate increased pertussis activity and inform the public health decisions of epidemiologists, MOHs and local communicable disease managers. Furthermore, these results helped to guide public health action, particularly in areas of high pertussis activity. The methods presented in this paper could be adjusted to investigate and manage other communicable diseases.
Introduction
The 
Methods
Survey methods were based on the federal government online survey standards (1). The 2016 online survey was based on the 2011 survey and checked for face-validity. It included questions about the readership, how they liked the journal, how they received information on infectious diseases in general and how CCDR might be improved. Most of the survey questions were multiple choice format followed by a comments section which included a question about how to improve CCDR. Following pilot testing in both official languages, an invitation to complete the online survey was sent by email to CCDR's 4716 subscribers.
The survey was available online from September 7 to 28, 2016. Two reminders were sent to non-responders to optimize the participation rate. The participation rate was calculated by dividing the number of responders by the sum of responders, non-responders and the number of bounce-backs minus any email addresses found to be invalid. Analysis of the responses included descriptive statistics and a qualitative assessment of comments for themes.
Results
Canada Communicable Disease Report's readership and information sources
Of the 4716 subscribers, 17 emails were found to be invalid for a total of 4699 participants. Of those 549 surveys were completed for a participation rate of 12%. The majority of respondents indicated they worked in public health (61%), followed by clinical care (23%), academia (16%) and laboratory medicine (9%). This total exceeds 100% because it was possible to select more than one response option (for example, clinical care AND academia). Slightly less than 20% of respondents were 35 years of age or younger, about 40% were between 36-50 years old and 40% were over 50 years old. Almost 50% of respondents had been receiving CCDR for less than four years, which is consistent with the fact that the number of CCDR subscribers doubled since the 2011 survey.
Most readers were from Ontario and Quebec, although there were readers from almost every province and all of the territories, as well as from the United States, the European Union and elsewhere ( Figure 2) . Nearly half of all respondents noted they first heard about CCDR either at a conference or through a colleague or teacher.
The most common resources respondents used to obtain information about infectious diseases were websites (75%), colleagues (72%) and online literature searches (69%). Other sources were noted in the comments such as ProMED. When asked how they were most likely to obtain Canadian-specific information on infectious diseases and immunization, the top source was CCDR (72%), followed by local public health (52%), updates from province/territory (almost 50%) and the National Advisory Committee on Immunization (NACI) (50%) (Figure 3 ).
Feedback on the revitalized Canada Communicable Disease Report
Over 90% of respondents reported reading the articles in CCDR (always 15%, often 43%, sometimes 35%) and found the following types of articles to be useful or very useful:
• Rapid communication on outbreaks with potential to spread (90%) • PHAC or advisory committee guidelines for communicable diseases (87%) • Research articles on infectious disease topics of relevance to Canada (86%) • National surveillance reports on notifiable diseases (84%)Comments were provided by 62% of respondents (n=340) in the feedback section.
The most common strengths identified were CCDR's Canadian content, high quality and relevance. When asked "What do you like best about CCDR?" typical comments were: "Canadian, well written, evidence based", "interesting articles", "topical", "relevant to my work", and "concise and reliable." 
SURVEY
Suggestions for improvement and next steps
When asked "What do you think is the most important way we can improve CCDR?" almost 50% of respondents commented (n=266). The most frequent comments were: "keep up the good work" and "get indexed on PubMed/Medline". Other suggestions were:
• Reach out to students in universities and give presentations • Include more foodborne outbreak reports • Have more articles from authors across Canada • Be as timely as possible especially with surveillance data and outbreak reports
When asked, 40% of respondents stated they would like to access CCDR using a tablet or smartphone app. However, if an app included CCDR and other resources, such as the Canadian Immunization Guide, the Sexually Transmitted Infection Guide and the Tuberculosis Standards, 46% of respondents stated they would download it. A typical comment was "I would like to be able to access CCDR from my iPhone."
Discussion
CCDR readers come from across Canada and around the world. Most respondents work in public health and clinical care. Readers like the CCDR's revitalized content, high quality and relevance and identify the journal as their top source for Canadian-specific infectious disease information. In 2011, CCDR readers asked for more rapid communications, summaries of advisory committee recommendations and research articles on infectious diseases. These types of articles have been published in CCDR over the last three years and 85-90% of readers have found them useful.
Since CCDR was revitalized, its subscription rate has more than doubled. Survey responders suggested more outreach, Canadian authors, increased timeliness and a mobile application. However, the most common suggestion for improvement was to list the journal with PubMed.
The key limitation of this survey is the response rate of 12%. Although this is not unusual for an online survey, there is no assurance that the respondents are representative of the entire CCDR readership.
The readership survey confirms that CCDR has come a long way in the past five years and its readers find it to be their go-to source for practical, authoritative information on infectious diseases in Canada. We are pleased to announce that CCDR has passed the scientific review for PubMed and full text articles will be available through PubMed Central in 2017.
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